431
Participants
Start Date
October 28, 2009
Primary Completion Date
September 2, 2016
Study Completion Date
April 10, 2020
Bevacizumab
Given IV
Carboplatin
Given IV
Cisplatin
Given IP
Laboratory Biomarker Analysis
Correlative studies
Paclitaxel
Given IV or IP
Veliparib
Given PO
Memorial Sloan Kettering Cancer Center, New York
Roswell Park Cancer Institute, Buffalo
Fox Chase Cancer Center, Philadelphia
MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
University of Virginia Cancer Center, Charlottesville
Virginia Commonwealth University/Massey Cancer Center, Richmond
Augusta University Medical Center, Augusta
University of Alabama at Birmingham Cancer Center, Birmingham
Ohio State University Comprehensive Cancer Center, Columbus
Riverside Methodist Hospital, Columbus
Case Western Reserve University, Cleveland
MetroHealth Medical Center, Cleveland
Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland
Hillcrest Hospital Cancer Center, Mayfield Heights
Cleveland Clinic Foundation, Cleveland
University of Iowa/Holden Comprehensive Cancer Center, Iowa City
University of Wisconsin Hospital and Clinics, Madison
University of Chicago Comprehensive Cancer Center, Chicago
Washington University School of Medicine, St Louis
University of Oklahoma Health Sciences Center, Oklahoma City
University of Colorado Hospital, Aurora
Women and Infants Hospital, Providence
Collaborators (1)
NRG Oncology
OTHER
National Cancer Institute (NCI)
NIH